ConductScience.org, home

Paper11387

Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes.

Harms HH. Life Sci, 1976. Cited by 27 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes. Papers, record 11387. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/11387

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Stereochemical aspects of beta-adrenoceptor antagonist-receptor interaction in adipocytes. Differentiation of beta-adrenoceptors in human and rat adipocytes.
PubMed
Journal
Life Sci
PubMed
Year
1976
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
27
iCite
Relative citation ratio, by iCite
0.75
iCite
Revised in PubMed
2019-07-01
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Harms HHH H

Source PubMed

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Adipose TissueMajor topic
Adrenergic beta-AntagonistsMajor topic
Receptors, AdrenergicMajor topic
Receptors, Adrenergic, betaMajor topic
Animals
Epididymis
Fatty Acids, Nonesterified
Humans
Kinetics
Male
Rats
Species Specificity
Stereoisomerism
Structure-Activity Relationship

Source PubMed

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.

PMIDTitleJournalYearIn PapersSource
38,136,585Is the β3-Adrenoceptor a Valid Target for the Treatment of Obesity and/or Type 2 Diabetes?Biomolecules2023https://conductscience.org/library/papers/38136585PubMed
26,612,506Longitudinal trends and subgroup analysis in publication patterns for preclinical data of newly approved drugs.Naunyn Schmiedebergs Arch Pharmacol2016https://conductscience.org/library/papers/26612506PubMed
18,612,674The discovery of drugs for obesity, the metabolic effects of leptin and variable receptor pharmacology: perspectives from beta3-adrenoceptor agonists.Naunyn Schmiedebergs Arch Pharmacol2008https://conductscience.org/library/papers/18612674PubMed
6,125,168Beta-adrenoceptor blocking agents and lipolysis.Br J Clin Pharmacol1982https://conductscience.org/library/papers/6125168PubMed
2,983,800Atypical characteristics of the beta-adrenoceptor mediating cyclic AMP generation and lipolysis in the rat adipocyte.Br J Pharmacol1985https://conductscience.org/library/papers/2983800PubMed
23,133
Blockade of isoprenaline-induced changes in plasma free fatty acids, immunoreactive insulin levels and plasma renin activity in healthy human subjects, by propranolol, pindolol, practolol, atenolol, metoprolol and acebutolol.
Br J Clin Pharmacol1978https://conductscience.org/library/papers/23133PubMed

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/11387

GET https://conductscience.org/api/papers/v1/11387/authors